SOUTH SAN FRANCISCO, Calif., Nov. 10, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that OXiGENE Management will present a corporate overview and update at the Merriman Curhan Ford Investor Summit at 12:00 noon EST (9:00 a.m. PST) today at the Sofitel Hotel in New York City, N.Y.
The Company will also present a corporate overview and update at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17th, at 1:10 p.m. EST (10:10 a.m. PST), in the St. Regis Hotel in New York City, N.Y.
A live and archived webcast of each presentation can be accessed for 30 days following the presentations by clicking on the Investors tab at www.oxigene.com.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969